Review outlines developments in beta- and alpha-emitting PSMA radioligands in advanced prostate cancer, highlighting novel actinium- and lead-based therapeutic approaches.
management of patients with advanced prostate cancer, firmly anchored in clinical guidelines [8].This article provides an update on established PSMA theranostics using beta-emitting ligands, based on major clinical trial results.It then continues with an overview of more recent developments in the field of PSMA radiotheranostics, focusing on alpha-based approaches, in particular on actinium-based and, subsequently, astatine-and leadbased radiopharmaceutical therapies (RPTs).
No takes yet. Share an insight, caveat, or question.
Holzgreve et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: